Improving Hepatocellular Carcinoma Screening
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorNaik Vietti Violi
About this trial
This is a monocentric, single blind, interventional, single arm study. It is designed to compare the rates of detection of hepatocellular carcinoma (HCC) by ultrasound (US) used in clinical routine vs. abbreviated magnetic resonance imaging (AMRI). The hypothesis is that dynamic AMRI with extracellular contrast agent injection has a higher patient-level detection rate of HCC than screening US and non-contrast AMRI.
Interested and eligible patients will be enrolled and undergo HCC screening rounds including US +/- contrast-enhanced US (clinical routine) and screening MRI within the same week bi-annually.
Eligibility criteria
Qualifiers
All adult patients with chronic liver disease and indication for HCC screening according to the European Association for the Study of the Liver recommendations.
Informed Consent signed by the subject
Disqualifiers
History of HCC
History of other malignancy
Prior liver nodule categorized as LI-RAD 4, 5 or M
History of liver transplantation
Trial design
Treatments tested in this trial
- MRI
Treatment groups
330 Participants
are divided into 1 treatment groupSponsors and collaborators
Naik Vietti Violi
Lead sponsor
University of Lausanne Hospitals
Sponsor institution
Source ClinicalTrials.gov